Follow
Frederick W. Thielen
Frederick W. Thielen
Assistant professor, Erasmus School of Health Policy and Management
Verified email at eshpm.eur.nl - Homepage
Title
Cited by
Cited by
Year
Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation
VJ Nijenhuis, J Brouwer, R Delewi, RS Hermanides, W Holvoet, ...
New England Journal of Medicine 382 (18), 1696-1707, 2020
1602020
Aspirin with or without clopidogrel after transcatheter aortic-valve implantation
J Brouwer, VJ Nijenhuis, R Delewi, RS Hermanides, W Holvoet, ...
New England Journal of Medicine 383 (15), 1447-1457, 2020
1592020
How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3)
FW Thielen, G Van Mastrigt, LT Burgers, WM Bramer, HJM Majoie, ...
Expert Review of Pharmacoeconomics & Outcomes Research 16 (6), 705-721, 2016
622016
Long-term economic consequences of child maltreatment: a population-based study
FW Thielen, M Ten Have, R de Graaf, P Cuijpers, A Beekman, S Evers, ...
European child & adolescent psychiatry 25 (12), 1297-1305, 2016
332016
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens
LEM Oosten, MED Chamuleau, FW Thielen, LC de Wreede, C Siemes, ...
Annals of hematology 97 (2), 255-266, 2018
272018
Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view
FW Thielen, A van Dongen‐Leunis, AMM Arons, JR Ladestein, ...
European journal of haematology 105 (2), 203-215, 2020
142020
Kindermishandeling: economische gevolgen op lange termijn1
P Speetjens, F Thielen, M Ten Have, R De Graaf, F Smit
Tijdschrift voor psychiatrie 58 (10), 706-711, 2016
122016
Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future
R Heine, FW Thielen, M Koopmanschap, MJ Kersten, H Einsele, U Jaeger, ...
Hemasphere 5 (2), 2021
102021
Designing and testing of a health-economic Markov model for prevention and treatment of early psychosis
BFM Wijnen, FW Thielen, S Konings, T Feenstra, M Van Der Gaag, ...
Expert review of pharmacoeconomics & outcomes research 20 (3), 269-279, 2020
52020
Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model
FW Thielen, HM Blommestein, LEM Oosten, FG Calkoen, AC Lankester, ...
European Journal of Haematology 101 (5), 676-683, 2018
42018
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
FW Thielen, NC BŁyŁkkaramikli, R Riemsma, D Fayter, N Armstrong, ...
Pharmacoeconomics 37 (8), 975-984, 2019
32019
Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
FW Thielen, MJ Kersten, P Kuizenga, M Hoogendoorn, EFM Posthuma, ...
Expert review of anticancer therapy 21 (12), 1411-1422, 2021
22021
Cost of health care for paediatric patients with sickle cell disease: an analysis of resource use and costs in a European country
FW Thielen, ME Houwing, MH Cnossen, IA al Hadithy‐Irgiztseva, ...
Pediatric Blood & Cancer 67 (9), e28588, 2020
22020
Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease
FW Thielen, HM Blommestein, CA Uyl-de Groot
Biology of Blood and Marrow Transplantation 22 (11), 2109-2110, 2016
22016
Policy evaluation and behavioral economics
K Ruggeri, JP Stuhlreyer, JE Immonen, S Mareva, M Friedemann, AF Paul, ...
Psychology and Behavioral Economics, 226-246, 2021
12021
Child maltreatment: long-term economic consequences and implications
P Speetjens, F Thielen, M Ten Have, R de Graaf, F Smit
Tijdschrift voor Psychiatrie 58 (10), 706-711, 2016
12016
Current Challenges in Health Technology Assessment: Assessing costs and cost-effectiveness of novel treatments in haemato-oncology
F Thielen
2020
The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease
ME Houwing, F Thielen, APJ de Pagter, JA Hazelzet, H Blommestein, ...
Blood 134, 1030, 2019
2019
Policy evaluation
Kai Ruggeri, Julia P. Stuhlreyer, Johanna Immonen, Silvana Mareva ...
Behavioral Insight for Public Policy: Concepts and Cases, 288, 2018
2018
Second-Line Treatment for Steroid-Refractory Graft-Versus-Host Disease with Mesenchymal Stromal Cells. A Conceptual Disease Model
F Thielen, HM Blommestein, L Oosten, W Fibbe, K Le Blanc, F Locatelli, ...
Value in Health 20 (9), A545-A546, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20